Can a common antioxidant ease MPN symptoms?

NCT ID NCT05123365

Recruiting now Symptom relief Sponsor: University of California, Irvine Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests N-Acetylcysteine (N-AC), an antioxidant, in 27 adults with myeloproliferative neoplasms (MPN) like essential thrombocythemia, polycythemia vera, or myelofibrosis. The goal is to find the best dose that safely reduces symptom burden, measured by a symptom score. Participants continue their usual MPN treatments while taking N-AC.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: N-Acetylcysteine (N-AC)
What this could lead to: If it works, this could point toward a well-tolerated way to reduce symptom burden for people with MPN.
What could go wrong: This is a small, early-phase study (27 people) focused on finding the right dose, not proving effectiveness. It may not lead to a new standard treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESSENTIAL THROMBOCYTHEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired polycythemia vera essential thrombocythemia myelofibrosis Myeloproliferative Disorders myeloproliferative neoplasm primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESSENTIAL THROMBOCYTHEMIA MPN MYELOFIBROSIS MYELOPROLIFERATIVE NEOPLASM POLYCYTHEMIA VERA

Contacts and locations

Locations

Chao Family Comprehensive Cancer Center, University of California, Irvine
ACTIVE_NOT_RECRUITING

Orange, California, 92868, United States
University of California, Irvine
RECRUITING

Irvine, California, 92617, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.